InCarda Therapeutics
Pioneering inhaled medications for cardiovascular conditions
Pioneering inhaled medications for cardiovascular conditions
InCarda Therapeutics is a clinical stage drug delivery company that is focused on pioneering inhaled medications for cardiovascular conditions. The company's lead product under development is an inhaled therapy designed to treat paroxysmal atrial fibrillation (PAF), a common atrial arrhythmia. InCarda Therapeutics was founded in 2009 and is based in the United States. It operates within the biotechnology, health care, and health and wellness industries. The most recent funding round was a Series C investment of $30.00M, which was secured on October 21, 2020. The investors in this round included HealthCap, Innoviva, Morningside Venture Investments, and Deerfield.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series C | $30.00M | 4 |
|
21 Oct 2020 |
| Series B | $42.00M | 5 |
|
08 Nov 2018 |
| Venture Round | Unknown | 1 |
|
01 Jan 2017 |
| Venture Round | Unknown | 1 |
|
12 Jul 2016 |
| Series A | $5.00M | 1 |
|
28 Apr 2015 |
No recent news or press coverage available for InCarda Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.
